Developments and current pharmacotherapeutic recommendations for ankylosing spondylitis.
The introduction of anti-TNFalpha therapy into the field of rheumatology has led to dramatic improvements in patient care, perhaps the most remarkable being in the management of ankylosing spondylitis. As experience with these compounds grows, their place in therapeutic strategy is becoming clearer, and it has been possible to develop evidence- and expertise-based recommendations for the management of ankylosing spondylitis to aid the clinician in patient care. This review outlines treatment advances in ankylosing spondylitis, including the use of anti-TNFalpha agents, and how these have been incorporated into clinical recommendations for daily use.
Zochling
Jane
J
Rheumazentrum-Ruhrgebiet, Landgrafenstr. 15, 44652 Herne, Germany. Zochling@rheumazentrum-ruhrgebiet.de
Braun
Jürgen
J
D000818:Animals; D018501:Antirheumatic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D017410:Practice Guidelines as Topic; D013167:Spondylitis, Ankylosing / Q000188:drug therapy* / Q000378:metabolism / Q000534:rehabilitation; D013678:Technology, Pharmaceutical / Q000639:trends*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000378:metabolism
D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha